Literature DB >> 29787764

APOBEC3B Nuclear Localization Requires Two Distinct N-Terminal Domain Surfaces.

Daniel J Salamango1, Jennifer L McCann1, Özlem Demir2, William L Brown1, Rommie E Amaro2, Reuben S Harris3.   

Abstract

The APOBEC3 family of cytosine deaminases catalyzes the conversion of cytosines-to-uracils in single-stranded DNA. Traditionally, these enzymes are associated with antiviral immunity and restriction of DNA-based pathogens. However, a role for these enzymes in tumor evolution and metastatic disease has also become evident. The primary APOBEC3 candidate in cancer mutagenesis is APOBEC3B (A3B) for three reasons: (1) A3B mRNA is upregulated in several different cancers, (2) A3B expression and mutational loads correlate with poor clinical outcomes, and (3) A3B is the only family member known to be constitutively nuclear. Previous studies have mapped non-canonical A3B nuclear localization determinants to a single surface-exposed patch within the N-terminal domain (NTD). Here, we show that A3B has an additional, distinct, surface-exposed NTD region that contributes to nuclear localization. Disruption of residues within the first 30 amino acids of A3B (import surface 1) or loop 5/α-helix 3 (import surface 2) completely abolish nuclear localization. These import determinants also graft into NTDs of related family members and mediate re-localization from cell-wide-to-nucleus or cytoplasm-to-nucleus. These findings demonstrate that both sets of residues are required for non-canonical A3B nuclear localization and describe unique surfaces that may serve as novel therapeutic targets.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  APOBEC3B; cancer genomic DNA deaminase; nuclear import; retrovirus restriction factor; subcellular localization

Mesh:

Substances:

Year:  2018        PMID: 29787764      PMCID: PMC6456046          DOI: 10.1016/j.jmb.2018.04.044

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  68 in total

1.  Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif.

Authors:  Brian P Doehle; Alexandra Schäfer; Bryan R Cullen
Journal:  Virology       Date:  2005-09-01       Impact factor: 3.616

2.  APOBEC3B and APOBEC3F inhibit L1 retrotransposition by a DNA deamination-independent mechanism.

Authors:  Mark D Stenglein; Reuben S Harris
Journal:  J Biol Chem       Date:  2006-04-28       Impact factor: 5.157

3.  Evidence for APOBEC3B mRNA and protein expression in oral squamous cell carcinomas.

Authors:  Galinos Fanourakis; Konstantinos Tosios; Nikolaos Papanikolaou; Ioulia Chatzistamou; Marios Xydous; Sofia Tseleni-Balafouta; Alexandra Sklavounou; Gerassimos E Voutsinas; Heleni Vastardis
Journal:  Exp Mol Pathol       Date:  2016-11-04       Impact factor: 3.362

4.  The role of amino-terminal sequences in cellular localization and antiviral activity of APOBEC3B.

Authors:  Vladimir Pak; Gisela Heidecker; Vinay K Pathak; David Derse
Journal:  J Virol       Date:  2011-06-29       Impact factor: 5.103

5.  Identification of APOBEC3DE as another antiretroviral factor from the human APOBEC family.

Authors:  Ying Dang; Xiaojun Wang; Walter J Esselman; Yong-Hui Zheng
Journal:  J Virol       Date:  2006-08-18       Impact factor: 5.103

6.  A polypeptide domain that specifies migration of nucleoplasmin into the nucleus.

Authors:  C Dingwall; S V Sharnick; R A Laskey
Journal:  Cell       Date:  1982-09       Impact factor: 41.582

7.  The nucleoplasmin nuclear location sequence is larger and more complex than that of SV-40 large T antigen.

Authors:  C Dingwall; J Robbins; S M Dilworth; B Roberts; W D Richardson
Journal:  J Cell Biol       Date:  1988-09       Impact factor: 10.539

8.  Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B.

Authors:  Valdimara C Vieira; Brandon Leonard; Elizabeth A White; Gabriel J Starrett; Nuri A Temiz; Laurel D Lorenz; Denis Lee; Marcelo A Soares; Paul F Lambert; Peter M Howley; Reuben S Harris
Journal:  mBio       Date:  2014-12-23       Impact factor: 7.867

9.  Merkel Cell Polyomavirus Exhibits Dominant Control of the Tumor Genome and Transcriptome in Virus-Associated Merkel Cell Carcinoma.

Authors:  Gabriel J Starrett; Christina Marcelus; Paul G Cantalupo; Joshua P Katz; Jingwei Cheng; Keiko Akagi; Manisha Thakuria; Guilherme Rabinowits; Linda C Wang; David E Symer; James M Pipas; Reuben S Harris; James A DeCaprio
Journal:  MBio       Date:  2017-01-03       Impact factor: 7.867

Review 10.  Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution.

Authors:  S Venkatesan; R Rosenthal; N Kanu; N McGranahan; J Bartek; S A Quezada; J Hare; R S Harris; C Swanton
Journal:  Ann Oncol       Date:  2018-03-01       Impact factor: 32.976

View more
  14 in total

1.  APOBEC3H Subcellular Localization Determinants Define Zipcode for Targeting HIV-1 for Restriction.

Authors:  Daniel J Salamango; Jordan T Becker; Jennifer L McCann; Adam Z Cheng; Özlem Demir; Rommie E Amaro; William L Brown; Nadine M Shaban; Reuben S Harris
Journal:  Mol Cell Biol       Date:  2018-11-13       Impact factor: 4.272

Review 2.  The spectrum of APOBEC3 activity: From anti-viral agents to anti-cancer opportunities.

Authors:  Abby M Green; Matthew D Weitzman
Journal:  DNA Repair (Amst)       Date:  2019-09-13

3.  A Conserved Mechanism of APOBEC3 Relocalization by Herpesviral Ribonucleotide Reductase Large Subunits.

Authors:  Adam Z Cheng; Sofia N Moraes; Claire Attarian; Jaime Yockteng-Melgar; Matthew C Jarvis; Matteo Biolatti; Ganna Galitska; Valentina Dell'Oste; Lori Frappier; Craig J Bierle; Stephen A Rice; Reuben S Harris
Journal:  J Virol       Date:  2019-11-13       Impact factor: 5.103

4.  The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1.

Authors:  Jennifer L McCann; Madeline M Klein; Evelyn M Leland; Emily K Law; William L Brown; Daniel J Salamango; Reuben S Harris
Journal:  J Biol Chem       Date:  2019-06-19       Impact factor: 5.157

5.  The DNA Cytosine Deaminase APOBEC3B is a Molecular Determinant of Platinum Responsiveness in Clear Cell Ovarian Cancer.

Authors:  Artur A Serebrenik; Prokopios P Argyris; Matthew C Jarvis; William L Brown; Martina Bazzaro; Rachel I Vogel; Britt K Erickson; Sun-Hee Lee; Krista M Goergen; Matthew J Maurer; Ethan P Heinzen; Ann L Oberg; Yajue Huang; Xiaonan Hou; S John Weroha; Scott H Kaufmann; Reuben S Harris
Journal:  Clin Cancer Res       Date:  2020-02-14       Impact factor: 12.531

Review 6.  The current toolbox for APOBEC drug discovery.

Authors:  Michael J Grillo; Katherine F M Jones; Michael A Carpenter; Reuben S Harris; Daniel A Harki
Journal:  Trends Pharmacol Sci       Date:  2022-05       Impact factor: 17.638

Review 7.  Examination of the APOBEC3 Barrier to Cross Species Transmission of Primate Lentiviruses.

Authors:  Amit Gaba; Ben Flath; Linda Chelico
Journal:  Viruses       Date:  2021-06-07       Impact factor: 5.048

8.  Interaction with the CCT chaperonin complex limits APOBEC3A cytidine deaminase cytotoxicity.

Authors:  Abby M Green; Rachel A DeWeerd; David R O'Leary; Ava R Hansen; Katharina E Hayer; Katarzyna Kulej; Ariel S Dineen; Julia H Szeto; Benjamin A Garcia; Matthew D Weitzman
Journal:  EMBO Rep       Date:  2021-08-04       Impact factor: 9.071

9.  A Rabbit Monoclonal Antibody against the Antiviral and Cancer Genomic DNA Mutating Enzyme APOBEC3B.

Authors:  William L Brown; Emily K Law; Prokopios P Argyris; Michael A Carpenter; Rena Levin-Klein; Alison N Ranum; Amy M Molan; Colleen L Forster; Brett D Anderson; Lela Lackey; Reuben S Harris
Journal:  Antibodies (Basel)       Date:  2019-09-10

10.  MagnEdit-interacting factors that recruit DNA-editing enzymes to single base targets.

Authors:  Jennifer L McCann; Daniel J Salamango; Emily K Law; William L Brown; Reuben S Harris
Journal:  Life Sci Alliance       Date:  2020-02-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.